BridgeBio
IPO
We exist to bring meaningful medicines to patients quickly & safely.
- Headquarters
- San Francisco Bay Area, California
- Employees
- 201–500
- Founded
- 2014
- Business Model
- Other
- Website
- bridgebio.com
- Total Funding
- $909.2M
- Last Round
- $475.0M Convertible NoteMar 2020
About
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. It has a late-stage investigational pipeline including Acoramidis for ATTRv, BBP-418 for LGMD2I/R9, Encaleret for ADH1 and hypoparathyroidism, Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan Disease.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account